Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 244

Sort by

Sort Order Select

Journal Articles

Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL

Blood (2025) 146 (Supplement 1): 681.

https://doi.org/10.1182/blood-2025-681

Published: 2025

Journal Articles

Characteristics and outcomes for patients with concomitant myeloproliferative neoplasms (MPN) and autoimmune disorders

Blood (2025) 146 (Supplement 1): 2037.

https://doi.org/10.1182/blood-2025-2037

Published: 2025

Journal Articles

Avapritinib achieves deep and durable symptom control with a well-tolerated safety profile in ism: Long-term outcomes from pioneer

Blood (2025) 146 (Supplement 1): 2024.

https://doi.org/10.1182/blood-2025-2024

Published: 2025

Journal Articles

A phase 2, open-label study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of DISC-3405 in participants with polycythemia vera (PV)

Blood (2025) 146 (Supplement 1): 2053.

https://doi.org/10.1182/blood-2025-2053

Published: 2025

Journal Articles

RALLY MF: A phase 2 Study of DISC-0974, an anti-hemojuvelin antibody, in patients with myelofibrosis and anemia

Naseema Gangat, Ayalew Tefferi, Prithviraj Bose, Elizabeth Hexner, Laura Michaelis, Aaron Gerds, Akriti Jain, Prioty Islam, Raajit Rampal, Ronan Swords, Moshe Talpaz, Kristen Pettit, Sima Bhatt, Akshay Buch, Olivia Pelletier, Will Savage, Anna Halpern

Blood (2025) 146 (Supplement 1): 2042.

https://doi.org/10.1182/blood-2025-2042

Published: 2025

Journal Articles

The combination of ruxolitinib and the CDK4/6 inhibitor abemaciclib demonstrates safety and efficacy in previously treated myelofibrosis patients: Results of A phase I study

Jan Philipp Bewersdorf, Andriy Derkach, Amer Zeidan, Emily Burton, Katherine Kan, Marissa Giuliani, Jeetayu Biswas, Michael Mauro, Brian Chernak, Tamanna Haque, Nikolai Podoltsev, Ross Levine, Prithviraj Bose, Raajit Rampal

Blood (2025) 146 (Supplement 1): 3814.

https://doi.org/10.1182/blood-2025-3814

Published: 2025

Journal Articles

Clinical, molecular, and demographic features of systemic mastocytosis: Analysis of a large cohort

Annie Hoai Nguyen, Wei Xiao, Ivo Veletic, Taghi Manshouri, Julie Braish, Georgina El Hajjar, Ghayas Issa, Naveen Pemmaraju, Lucia Masarova, Prithviraj Bose, Hussein Abbas

Blood (2025) 146 (Supplement 1): 3813.

https://doi.org/10.1182/blood-2025-3813

Published: 2025

Journal Articles

Preliminary experience from the ODYSSEY trial: Efficacy and safety of momelotinib in combination with luspatercept in patients with transfusion-dependent myelofibrosis

Prithviraj Bose, Jean-Christophe Ianotto, Regina Garcia-Delgado, Jonathan Abbas, Jasmine Sahni, Dwaipayan Patnaik, Catherine Ellis, Sunny Kim, Vikas Gupta

Blood (2025) 146 (Supplement 1): 3803.

https://doi.org/10.1182/blood-2025-3803

Published: 2025

Journal Articles

The activin receptor-like kinase-2 inhibitor zilurgisertib (INCB000928) as monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis: Phase 1/2 study final results

Blood (2025) 146 (Supplement 1): 3795.

https://doi.org/10.1182/blood-2025-3795

Published: 2025

Journal Articles

Target dose delivery comparison: Ibrutinib + venetoclax vs. acalabrutinib + venetoclax in treatment-Naïve CLL patients in prospective clinical trials

Mahesh Swaminathan, Nitin Jain, Alexandra Lovell, Ashley Dinh, Alessandra Ferrajoli, Jan Burger, Musa Yilmaz, Tapan Kadia, Lucia Masarova, Yesid Alvarado Valero, Prithviraj Bose, Farhad Ravandi, Koji Sasaki, Wei Qiao, Zhouxuan Li, Naveen Garg, Michael Keating, William Wierda

Blood (2025) 146 (Supplement 1): 5687.

https://doi.org/10.1182/blood-2025-5687

Published: 2025

Journal Articles

Long progression-free survival with venetoclax consolidation in patients with high-risk chronic lymphocytic leukemia treated with ibrutinib.

Vishrut Shah, Philip Thompson, Grace Nie, Nitin Jain, Blanche Anderson, Tapan Kadia, Prithviraj Bose, Naveen Pemmaraju, Nicholas Short, Sa Wang, Jeffrey Jorgensen, Christine Peterson, William Wierda, Alessandra Ferrajoli

Blood (2025) 146 (Supplement 1): 5686.

https://doi.org/10.1182/blood-2025-5686

Published: 2025

Journal Articles

Real-world treatment duration of ruxolitinib and use of transfusion among 2268 patients with myelofibrosis: An analysis of the Medicare fee-for-service claims database

Prithviraj Bose, Taylor Schwartz, Jennifer Repp, Alexis Garduno, Shayna Adams, Ahmad Naim, Valkal Bhatt, Jingbo Yu

Blood (2025) 146 (Supplement 1): 6391.

https://doi.org/10.1182/blood-2025-6391

Published: 2025

Journal Articles

Quantitative profiling and clinical correlative analysis of fibrocytes and mesenchymal stromal cells in myelofibrosis spleen

Ivo Veletic, Taghi Manshouri, Christopher Pacheco, Christopher Ly, C. Cameron Yin, Jared Burks, Naveen Pemmaraju, Lucia Masarova, Prithviraj Bose, Hussein Abbas, Andrew Dunbar

Blood (2025) 146 (Supplement 1): 5542.

https://doi.org/10.1182/blood-2025-5542

Published: 2025

Journal Articles

Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study

Blood (2025) 146 (Supplement 1): 910.

https://doi.org/10.1182/blood-2025-910

Published: 2025

Journal Articles

Dose intensive regimen of CK0804 tregs in myelofibrosis

Lucia Masarova, Mehrdad Abedi, Naveen Pemmaraju, Prithviraj Bose, Tapan Kadia, Jo Ishizawa, Guillermo Montalban-Bravo, Tara Sadeghi, Simrit Parmar, Hagop Kantarjian

Blood (2025) 146 (Supplement 1): 5602.

https://doi.org/10.1182/blood-2025-5602

Published: 2025

Journal Articles

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study

Blood (2025) 146 (Supplement 1): 2018.

https://doi.org/10.1182/blood-2025-2018

Published: 2025

Journal Articles

Correlation between interleukin (IL)-8 and tumor necrosis factor (TNF)-alpha levels and overall survival in patients (pts) with myelofibrosis (MF) relapsed or refractory (R/R) to a Janus-associated kinase inhibitor (JAKi) treated with imetelstat (IME) in the imbark trial

John Mascarenhas, Claire Harrison, Alessandro Lucchesi, Angela Fleischman, Rami Komrokji, Alessandro Maria Vannucchi, Jean-Jacques Kiladjian, Yiqun Yang, Libo Sun, Ying Wan, Michelle Mudge-Riley, Tymara Berry, Faye Feller, Fei Huang, Prithviraj Bose

Blood (2025) 146 (Supplement 1): 5585.

https://doi.org/10.1182/blood-2025-5585

Published: 2025

Journal Articles

Survival outcomes in ruxolitinib-treated patients with myelofibrosis following crossover to momelotinib: Application of the response to ruxolitinib at 6 months (RR6) prognostic model to SIMPLIFY-1

Raajit Rampal, Prithviraj Bose, Vikas Gupta, Francesca Palandri, Shiyuan Zhang, Jessica Lim, Fulya Sen Nikitas, Tom (sizhu) Liu, Jasmine Sahni, Catherine Ellis, Dwaipayan Patnaik, Florian Heidel, Francesco Passamonti

Blood (2025) 146 (Supplement 1): 5579.

https://doi.org/10.1182/blood-2025-5579

Published: 2025

Journal Articles

INCB057643, a bromodomain and extra-terminal protein inhibitor, in combination with ruxolitinib in patients with myelofibrosis: A phase 1 study of safety and efficacy

Blood (2025) 146 (Supplement 1): 5574.

https://doi.org/10.1182/blood-2025-5574

Published: 2025

Journal Articles

Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in jaki-naïve myelofibrosis: Study rationale and preliminary patient characteristics

Blood (2025) 146 (Supplement 1): 7353.

https://doi.org/10.1182/blood-2025-7353

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL

Characteristics and outcomes for patients with concomitant myeloproliferative neoplasms (MPN) and autoimmune disorders

Avapritinib achieves deep and durable symptom control with a well-tolerated safety profile in ism: Long-term outcomes from pioneer

A phase 2, open-label study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of DISC-3405 in participants with polycythemia vera (PV)

RALLY MF: A phase 2 Study of DISC-0974, an anti-hemojuvelin antibody, in patients with myelofibrosis and anemia

The combination of ruxolitinib and the CDK4/6 inhibitor abemaciclib demonstrates safety and efficacy in previously treated myelofibrosis patients: Results of A phase I study

Clinical, molecular, and demographic features of systemic mastocytosis: Analysis of a large cohort

Preliminary experience from the ODYSSEY trial: Efficacy and safety of momelotinib in combination with luspatercept in patients with transfusion-dependent myelofibrosis

The activin receptor-like kinase-2 inhibitor zilurgisertib (INCB000928) as monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis: Phase 1/2 study final results

Target dose delivery comparison: Ibrutinib + venetoclax vs. acalabrutinib + venetoclax in treatment-Naïve CLL patients in prospective clinical trials

Long progression-free survival with venetoclax consolidation in patients with high-risk chronic lymphocytic leukemia treated with ibrutinib.

Real-world treatment duration of ruxolitinib and use of transfusion among 2268 patients with myelofibrosis: An analysis of the Medicare fee-for-service claims database

Quantitative profiling and clinical correlative analysis of fibrocytes and mesenchymal stromal cells in myelofibrosis spleen

Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study

Dose intensive regimen of CK0804 tregs in myelofibrosis

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study

Correlation between interleukin (IL)-8 and tumor necrosis factor (TNF)-alpha levels and overall survival in patients (pts) with myelofibrosis (MF) relapsed or refractory (R/R) to a Janus-associated kinase inhibitor (JAKi) treated with imetelstat (IME) in the imbark trial

Survival outcomes in ruxolitinib-treated patients with myelofibrosis following crossover to momelotinib: Application of the response to ruxolitinib at 6 months (RR6) prognostic model to SIMPLIFY-1

INCB057643, a bromodomain and extra-terminal protein inhibitor, in combination with ruxolitinib in patients with myelofibrosis: A phase 1 study of safety and efficacy

Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in jaki-naïve myelofibrosis: Study rationale and preliminary patient characteristics

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only